CASE REPORTS
JOURNAL ARTICLE
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Add like
Add dislike
Add to saved papers

The efficacy of colchicine prophylaxis in articular gout--a reappraisal after 20 years.

Prophylactic colchicine remains an efficacious drug in preventing recurrent attacks of acute gouty arthritis. Its use is indicated especially in those patients with frequent and severe attacks, and in those with coexisting medical complications. In the present study which reviews the experience of 540 patients, 518 males and 22 females over a period of more than 20 yr, excellent results were obtained in approximately 82% of the patients, the response was satisfactory in 12%, and unsatisfactory in 5%. Hyperuricemia per se did not offset the efficacy of the prophylactic regimen. Factors affecting the failure of the regimen were most frequently related to associated uncontrolled medical complications or intemperate habits of food or alcoholic beverages. Few patients were colchicine intolerant. No hematologic or renal toxic effects were observed with extended and regular ingestion of colchicine. At the dosage employed for prophylaxis 0.5 or 1.0 mg, colchicine was most likely involved in the suppression of chemotactic factors involving the synovial lining cells. There is no evidence of chromosomal aberration or infertility. Discontinuance of the prophylactic program may be attempted in any patient who has been free from recurrent attacks for several years, particularly in older patients with no medical complications.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app